Acute Spinal Cord Injury Clinical Trial
Official title:
A Prospective, Multicentric, Randomized, Double Blind, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Patients of Acute Spinal Cord Injury
This was a prospective, multicentric, randomized, double blind, parallel, saline controlled Phase II clinical study to compare the safety and efficacy of PMZ-1620 (INN: Sovateltide) therapy along with standard supportive care in patients of acute spinal cord injury.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | July 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Adult males or females aged between 18 and 75 years inclusive 2. Able to give consent for participation on their own or through their Legally Acceptable Representative (LAR) 3. Able to cooperate in the completion of a standardized neurological examination by ISNCSCI standards (excludes patients who are on ventilator) 4. ISNCSCI Impairment Scale Grade "B," "C" or "D" based upon first ISNCSCI evaluation after arrival to the hospital is classified as motor or sensory incomplete 5. Willing and able to comply with the study Protocol 6. Women must be of non-childbearing potential or surgically sterile or willing to use adequate birth control; men who are sexually active will also be required to use adequate birth control 7. Able to receive the Investigational Drug within 48 hours of injury 8. Neurological Level of Injury between C5-C8, T1-T12, L1-L5 and S1-S5 based upon first ISNCSCI evaluation after arrival to the hospital 9. Patient with incomplete/partial damage/transaction as shown by CT or MRI scan 10. Patients with any other chronic conditions, who are stable with appropriate treatment Exclusion Criteria: 1. Previous history related to spinal cord disease 2. Patient on ventilator or requires ventilator 3. Patient with pathological fracture of vertebral column 4. Impairment Scale Grade "A" based upon first ISNCSCI assessment and classified as complete injury 5. One or more upper extremity muscle groups un-testable during baseline ISNCSCI examination 6. Concomitant head injury with a clinically significant abnormality on a head CT (head CT required only for patients suspected to have a brain injury at the discretion of the investigator) 7. Females who are breastfeeding or have a positive urine pregnancy test 8. Body mass index (BMI) of =35 kg/m2 at screening 9. Known immunodeficiency, including human immunodeficiency virus, or use of immunosuppressive or cancer chemotherapeutic drugs 10. Patient having rheumatoid arthritis 11. The participant has a clinically significant cardiovascular disorder or an abnormal electrocardiogram (ECG) at the discretion of the investigator 12. Pre-existent neurologic disorder which would preclude accurate evaluation and follow-up (i.e. Alzheimer's disease, Parkinson's disease, any psychiatric disorder with hallucinations/delusions/schizophrenia) 13. Patients who are currently participating in a clinical trial with an investigational drug or investigational device 14. Patients who, in the opinion of the investigator, are otherwise unsuitable for this study |
Country | Name | City | State |
---|---|---|---|
India | KLE's Dr. Prabhakar Kore Hospital & Medical Research Centre | Belgaum | |
India | Institute of Postgraduate Medical Education & Research and SSKM Hospital | Kolkata | |
India | King George's Medical University | Lucknow | |
India | Rahate Surgical Hospital & ICU | Nagpur | |
India | Indian Spinal Injury Centre | New Delhi |
Lead Sponsor | Collaborator |
---|---|
Pharmazz, Inc. |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of PMZ-1620 related adverse events | The primary objective of the study is to determine incidence of drug (PMZ-1620) related adverse events. | 90 days | |
Primary | Number of patients not receiving full treatment | Tolerability will be determined by the number of patients that do not receive all the 9 doses of PMZ-1620. | 90 days | |
Secondary | Changes in clinical progression of International Standards for Neurological Classification of spinal cord injury (ISNCSCI) | Statistically relevant changes in clinical progression of ASCI as measured by ISNCSCI scoring at one, two and three months after treatment. The International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) or more commonly referred to as the ASIA Impairment Scale (AIS), is a universal classification tool for Spinal Cord Injury based on a standardized sensory and motor assessment. Ranges from A to E where A = Complete and no sensory or motor function is preserved and E = Normal sensory and motor functions | 90 days | |
Secondary | Changes in walking index for spinal cord injury (WISCI) score | Statistically relevant changes in WISCI Score at one, two and three months after treatment. This test assesses the amount of physical assistance needed, as well as devices required, for walking following paralysis that results from SCI. It rank orders the ability of a person to walk 10 meter after a spinal cord injury from most to least severe impairment. A score from 0 to 20 is assigned, level 0: patient is unable to stand and/or participate in walking and level 20 patient ambulates with no devices, with brace and no assistance. | 90 days | |
Secondary | Changes in Spinal Cord Independence Measure (SCIM) score | Statistically relevant changes in SCIM score at one, two and three months after treatment. Spinal Cord Independence Measure (SCIM) scale is used to measure the disability to specifically address the ability of SCI patients to perform basic activities of daily living independently. The SCIM scores range from 0 to 100 where where a score of 0 defines total dependence and a score of 100 is indicative of complete independence. | 90 days | |
Secondary | Changes in MRI/CT | Changes in MRI/CT, before (baseline) and three months after treatment. Radiological evidence of transaction of spinal cord will be recorded by CT or MRI scan. In addition, edema, contusion, extent of spinal cord damage will be recorded. | 90 days | |
Secondary | Changes in electromyography (EMG) | Changes in EMG, before (baseline) and three months after treatment. Changes in nerve conduction parameters are recorded from the peroneal, tibial, and sural nerves. The presence of spontaneous activity (SA), including fibrillation and positive sharp waves are recorded in muscle groups vastus medialis, iliopsoas, tibialis anterior, medial gastrocnemius, and lumbar paraspinals. A decrease in nerve conduction parameters are indicative to greater severity. A high degree of abnormal SA on electromyographic testing represents the presence of muscle membrane instability. | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04811235 -
Optical Monitoring With Near-Infrared Spectroscopy for Spinal Cord Injury Trial
|
N/A | |
Completed |
NCT00406016 -
Acute Safety, Tolerability, Feasibility and Pharmacokinetics of Intrath. Administered ATI355 in Patients With Acute SCI
|
Phase 1 | |
Recruiting |
NCT05305118 -
TSCS for Acute SCI
|
N/A | |
Recruiting |
NCT05244408 -
"SCRIBBLE" Spinal Cord Injury Blood Biomarker Longitudinal Evaluation
|
||
Recruiting |
NCT05731986 -
Spinal Cord Transcutaneous Stimulation Effect on Blood Pressure in Acute Spinal Cord Injury (SCI)
|
N/A | |
Recruiting |
NCT06452264 -
Early Intervention for Information Processing Speed Deficits in Acute SCI: A Pilot Study
|
N/A | |
Recruiting |
NCT05426681 -
Spinal Cord Injury Neuroprotection With Glyburide
|
Phase 1 | |
Recruiting |
NCT04056988 -
tSCI Contrast Enhanced Ultrasound Study
|
Phase 4 | |
Recruiting |
NCT05745298 -
The Use of Functional Electrical Stimulation in Conjunction With Respiratory Muscle Training to Improve Unaided Cough in Individuals With Acute Spinal Cord Injury
|
N/A | |
Terminated |
NCT01750684 -
AC105 in Patients With Acute Traumatic Spinal Cord Injury
|
Phase 2 | |
Recruiting |
NCT04475224 -
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
|
Phase 3 | |
Enrolling by invitation |
NCT06030531 -
Spasticity and Functional Recovery After SCI
|
||
Active, not recruiting |
NCT03935724 -
Stem Cells in Spinal Cord Injury
|
Phase 2/Phase 3 | |
Recruiting |
NCT06000592 -
Safety, Feasibility, and Efficacy of TSCS on Stabilizing Blood Pressure for Acute Inpatients With SCI
|
N/A | |
Completed |
NCT02325414 -
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
|
Phase 2 | |
Recruiting |
NCT02034669 -
Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment
|
Phase 1/Phase 2 | |
Terminated |
NCT02232165 -
Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury
|
N/A | |
Completed |
NCT02260713 -
Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.
|
Phase 1/Phase 2 | |
Terminated |
NCT02524379 -
Spinal Cord Injury Neuroprotection With Glyburide
|
Phase 1/Phase 2 | |
Completed |
NCT01502631 -
Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)
|
Phase 2 |